NASDAQ:FGENFibroGen Stock Price, Forecast & News

FibroGen's stock was trading at $35.40 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, FGEN shares have increased by 24.9% and is now trading at $44.20.
View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for FibroGen.

FibroGen is scheduled to release its next quarterly earnings announcement on Monday, November 9th 2020.
View our earnings forecast for FibroGen.

FibroGen Inc (NASDAQ:FGEN) announced its earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.95) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by $0.31. The biopharmaceutical company earned $42.90 million during the quarter, compared to analyst estimates of $48.29 million. FibroGen had a negative return on equity of 57.40% and a negative net margin of 287.01%. The firm's quarterly revenue was down 77.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.26 earnings per share.
View FibroGen's earnings history.

5 brokers have issued 1 year price objectives for FibroGen's shares. Their forecasts range from $40.00 to $84.00. On average, they expect FibroGen's stock price to reach $58.40 in the next twelve months. This suggests a possible upside of 32.1% from the stock's current price.
View analysts' price targets for FibroGen.

News headlines about FGEN stock have been trending very positive on Saturday, InfoTrie reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. FibroGen earned a coverage optimism score of 4.0 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future.
View the latest news about FibroGen.

Some companies that are related to FibroGen include Catalent (CTLT), Teva Pharmaceutical Industries (TEVA), GRIFOLS S A/S (GRFS), GALAPAGOS NV/S (GLPG), Sarepta Therapeutics (SRPT), Dr.Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), Mylan (MYL), Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO) and ACADIA Pharmaceuticals (ACAD).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

(FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

FibroGen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include First Trust Advisors LP (1.89%), Principal Financial Group Inc. (0.29%), Candriam Luxembourg S.C.A. (0.24%), New York State Common Retirement Fund (0.24%), Swiss National Bank (0.20%) and Rhenman & Partners Asset Management AB (0.16%). Company insiders that own FibroGen stock include Christine Chung, Elias Kouchakji, Enrique A Conterno, James A Schoeneck, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura.
View institutional ownership trends for FibroGen.

FGEN stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, UBS Group AG, Alps Advisors Inc., WINTON GROUP Ltd, Candriam Luxembourg S.C.A., Envestnet Asset Management Inc., and Arizona State Retirement System. Company insiders that have sold FibroGen company stock in the last year include Christine Chung, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Thomas B Neff, and Thomas F Kearns Jr.
View insider buying and selling activity for FibroGen.

FGEN stock was purchased by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Principal Financial Group Inc., SG Americas Securities LLC, Mutual of America Capital Management LLC, Swiss National Bank, Rafferty Asset Management LLC, Mackay Shields LLC, and Virtu Financial LLC.
View insider buying and selling activity for FibroGen.

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of FGEN stock can currently be purchased for approximately $44.20.

FibroGen has a market capitalization of $3.94 billion and generates $256.58 million in revenue each year. The biopharmaceutical company earns $-76,970,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. FibroGen employs 461 workers across the globe.

The official website for FibroGen is www.fibrogen.com.

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]